BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Quigley Pharma Inc. 

Kells Building
621 N. Shady Retreat Road

P.O. Box 2071
Doylestown  Pennsylvania  18901  U.S.A.
Phone: 267-880-1100 Fax: 267-880-1153


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Pfizer Inc. (PFE) Unit Quigley Pharma Inc. (QGLY) To Exit Ch. 11 With $265M Asbestos Settlement 3/23/2011 6:50:16 AM    More...
Quigley Corporation (QGLY) Announces Final Results of Quigley Pharma Inc. (QGLY)'s Phase IIb Study 7/22/2009 8:34:28 AM    More...
Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma Inc. (QGLY), From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 5/19/2009 11:28:24 AM    More...
Quigley Pharma Inc. (QGLY) Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter 11/12/2008 8:27:23 AM    More...
Quigley Pharma Inc. (QGLY) Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound 8/1/2007 11:58:28 AM    More...
Quigley Pharma Inc. (QGLY) Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients 7/30/2007 8:59:29 AM    More...
Quigley Pharma Inc. (QGLY) Granted Patent For Prophylactic And Anti-Transmissivity Uses Of An Anti-Microbial Composition 2/12/2007 12:35:33 PM    More...
Quigley Pharma Inc. (QGLY) Broad Spectrum Anti-Viral QR-441(a) Shown To Be Effective Against Two Problematic Pathogens To The Poultry Industry 1/8/2007 3:06:44 PM    More...
Quigley Pharma Inc. (QGLY)'s QR-333 Phase IIb Clinical Study Has Commenced; Drug Product And Clinical Trial Sites Prepared For Phase IIb Study Of Lead Drug Candidate 11/20/2006 9:51:51 AM    More...
Quigley Pharma Inc. (QGLY)'s Radioprotective Compound QR-336 Shown To Be Most Effective In Oral And Subcutaneous Injection Dose Forms in Animal Model Study 10/3/2006 10:59:46 AM    More...
1234

//-->